OBJECTIVES:Neuropsychiatric toxicity is a common dose-limiting side effect of interferon therapy. The primary aim of this study was to determine whether patients receiving long-term low-dosepeginterferon therapy had a higher incidence of cognitive side effects compared with untreated patients enrolled in the Hepatitis C Antiviral Long-Term treatment against Cirrhosis (HALT-C) Trial. METHODS: A total of 129 patients with chronic hepatitis C and advanced fibrosis completed a battery of 10 neuropsychological tests and the Beck Depression Inventory at pretreatment baseline and at months 12, 24, 36, and 48 while receiving long-term peginterferonalpha2a (90 microg/week) or no therapy during the randomized phase of the HALT-C Trial. Cognitive impairment was defined as a global deficit score (GDS) > or = 1.0. RESULTS:The mean age was 51.2 years, 67% were male, and 42% had cirrhosis. After accounting for baseline GDS scores, the mean GDS scores did not significantly change over time (P=0.46) nor with treatment group (P=0.49). Cognitive function was also not influenced by medication adherence in the 66 patients receivingmaintenance peginterferon (P=0.14) after controlling for baseline GDS scores and time. Beck Depression scores did not significantly increase over time (P=0.60), nor did they vary by treatment group (P=0.74). Although 32% of patients experienced objective worsening of their liver disease during follow-up, the frequency and severity of cognitive impairment did not differ in those with and without disease progression (P=0.71). CONCLUSIONS: Measures of cognitive function were neither influenced by low-dose peginterferon treatment nor with objective evidence of liver disease progression in patients with advanced chronic hepatitis C prospectively followed up for 3.5 years.
RCT Entities:
OBJECTIVES:Neuropsychiatric toxicity is a common dose-limiting side effect of interferon therapy. The primary aim of this study was to determine whether patients receiving long-term low-dose peginterferon therapy had a higher incidence of cognitive side effects compared with untreated patients enrolled in the Hepatitis C Antiviral Long-Term treatment against Cirrhosis (HALT-C) Trial. METHODS: A total of 129 patients with chronic hepatitis C and advanced fibrosis completed a battery of 10 neuropsychological tests and the Beck Depression Inventory at pretreatment baseline and at months 12, 24, 36, and 48 while receiving long-term peginterferonalpha2a (90 microg/week) or no therapy during the randomized phase of the HALT-C Trial. Cognitive impairment was defined as a global deficit score (GDS) > or = 1.0. RESULTS: The mean age was 51.2 years, 67% were male, and 42% had cirrhosis. After accounting for baseline GDS scores, the mean GDS scores did not significantly change over time (P=0.46) nor with treatment group (P=0.49). Cognitive function was also not influenced by medication adherence in the 66 patients receiving maintenance peginterferon (P=0.14) after controlling for baseline GDS scores and time. Beck Depression scores did not significantly increase over time (P=0.60), nor did they vary by treatment group (P=0.74). Although 32% of patients experienced objective worsening of their liver disease during follow-up, the frequency and severity of cognitive impairment did not differ in those with and without disease progression (P=0.71). CONCLUSIONS: Measures of cognitive function were neither influenced by low-dose peginterferon treatment nor with objective evidence of liver disease progression in patients with advanced chronic hepatitis C prospectively followed up for 3.5 years.
Authors: Michael R Kraus; Arne Schäfer; Saskia Wissmann; Peter Reimer; Michael Scheurlen Journal: Clin Pharmacol Ther Date: 2005-01 Impact factor: 6.875
Authors: P Amodio; F Del Piccolo; P Marchetti; P Angeli; R Iemmolo; L Caregaro; C Merkel; G Gerunda; A Gatta Journal: Hepatology Date: 1999-06 Impact factor: 17.425
Authors: Daniel M Forton; Gavin Hamilton; Joanna M Allsop; Vijay P Grover; Keith Wesnes; Catherine O'Sullivan; Howard C Thomas; Simon D Taylor-Robinson Journal: J Hepatol Date: 2008-04-25 Impact factor: 25.083
Authors: William M Lee; Jules L Dienstag; Karen L Lindsay; Anna S Lok; Herbert L Bonkovsky; Mitchell L Shiffman; Gregory T Everson; Adrian M Di Bisceglie; Timothy R Morgan; Marc G Ghany; Chihiro Morishima; Elizabeth C Wright; James E Everhart Journal: Control Clin Trials Date: 2004-10
Authors: Robert J Fontana; Linas A Bieliauskas; Karen L Lindsay; Carla Back-Madruga; Elizabeth C Wright; Kristin K Snow; Anna S F Lok; Ziad Kronfol; Latha Padmanabhan Journal: Hepatology Date: 2007-05 Impact factor: 17.425
Authors: Jacinta Murray; Sarah L Fishman; Elizabeth Ryan; Francis J Eng; José L Walewski; Andrea D Branch; Susan Morgello Journal: J Neurovirol Date: 2008-01 Impact factor: 2.643
Authors: Robert J Fontana; Ziad Kronfol; Karen L Lindsay; Linas A Bieliauskas; Latha Padmanabhan; Carla Back-Madruga; Anna S F Lok; Anne M Stoddard Journal: Am J Gastroenterol Date: 2008-08-21 Impact factor: 10.864
Authors: Marilyn Huckans; Bret Fuller; Viva Wheaton; Sarah Jaehnert; Carilyn Ellis; Michael Kolessar; Daniel Kriz; Jeanne Renee Anderson; Kristin Berggren; Hannah Olavarria; Anna W Sasaki; Michael Chang; Kenneth D Flora; Jennifer M Loftis Journal: J Psychosom Res Date: 2014-08-07 Impact factor: 3.006
Authors: Kristin K Snow; Margaret C Bell; Anne M Stoddard; Teresa M Curto; Elizabeth C Wright; Jules L Dienstag Journal: Trials Date: 2014-05-07 Impact factor: 2.279